However, more tissue specific targeting of TXNIP is required for safer and efficient treatment of diabetes, since anti-oncogenic function of TXNIP has been well known [19,94,116,142,143,144,145,146,147,148,149,150,151,152,153], which suggests that chronic TXNIP inhibition in proliferative tissues such as the liver or intestine may increase the risk for tumorigenesis. Here, TXNIP is linked to diabetes mellitus.